Common Contracts
6 similar null contracts by Sunshine Biopharma, Inc, EZGO Technologies Ltd., Kaspien Holdings Inc., OKYO Pharma LTD
AEGIS CAPITAL CORP.EZGO Technologies Ltd. • September 13th, 2023 • Motorcycles, bicycles & parts • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the underwriter on a “firm commitment” basis, or a placement agent on a “best efforts” basis, in connection with the proposed shelf takedown (the “Offering”) by EZGO Technologies Ltd (collectively, with its subsidiaries and affiliates, the “Company”) of its ordinary shares (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Offering is premised. However, except as expressly provided herein, this engagement letter is not intended to be a binding legal document, as the agreement between the parties hereto on the matters relating to the Offering will be embodied in the Underwriting Agreement (as defined below) or Placement Agent Agreement (as defined below). It is contemplated that following the effectiveness of the registration statement relating to the Offering, this engagement letter will be replaced by the Und
AEGIS CAPITAL CORP.Sunshine Biopharma, Inc • May 16th, 2023 • Pharmaceutical preparations • New York
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units considered at the market under Nasdaq listing rules, with each unit consisting of one (1) share of common stock and two (2) warrants (“Warrants”), each to one (1) share of common stock exercisable at the Nasdaq at- the-market price of the common stock or consisting of one pre-funded warrant to purchase one (1) share of common stock and two (2) Warrants (collectively, the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company
AEGIS CAPITAL CORP.OKYO Pharma LTD • February 22nd, 2023 • Biological products, (no disgnostic substances) • New York
The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by OKYO Pharma Limited (collectively, with its subsidiaries and affiliates, the “Company”) of its American depositary shares (the “Securities”). This Agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Kaspien Holdings Inc. • July 14th, 2022 • Retail-record & prerecorded tape stores • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the lead placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Kaspien Holdings Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common stock (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Sunshine Biopharma, Inc • April 28th, 2022 • Services-commercial physical & biological research • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units considered at the market under Nasdaq listing rules, consisting of one (1) share of common stock and two warrants to purchase shares of common stock exercisable at the unit offering price (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Sunshine Biopharma, Inc • March 15th, 2022 • Services-commercial physical & biological research • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units consisting of one (1) share of common stock and one (1) warrant to purchase shares of common stock (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
